Changing European Commission policy in relation to biocides as agents driving antibiotic resistance
Submitting Institution
University of BirminghamUnit of Assessment
Clinical MedicineSummary Impact Type
PoliticalResearch Subject Area(s)
Medical and Health Sciences: Medical Microbiology
Summary of the impact
Antibiotic resistance has become one of the great challenges to human
health in the 21st century with
increasing numbers of isolates of many pathogenic bacteria being resistant
to front line, therapeutic
antibiotics. Recent evidence has suggested that antibiotic resistance can
be selected by exposure to
biocides, which are commonly used as disinfectants and preservatives.
Research at the University of Birmingham has shown the common mechanistic
links between antibiotic and
triclosan (a commonly used biocide) resistance. This research was used by
the European Commission as
evidence to support two reports published in 2009 and 2010 to inform
opinions as to the safety of biocide
use. These reports recommended specific new research avenues be funded and
that possible selection of
antibiotic resistance by biocides is a valid concern and were used as part
of the evidence base in
preparation of a new law which has come in to force across the European
Union.
Biocide use and sales in Europe have been controlled by the Biocidal
Products Directive since 1998. This
legislation has been superseded by the EU Biocides Regulation (published
May 2012, legally binding from
September 2013). This new legislation now includes a requirement for new
biocides to be demonstrated
not to select resistance to themselves or antibiotics in target organisms
before achieving registration; this
addition was informed by University of Birmingham research. This will
prevent biocides entering the
environment that exert a selective pressure and favour the emergence of
mutant bacteria with increased
biocide and antibiotic resistance. Thus the research described has had an
impact on policy debate and
the introduction of new legislation.
Underpinning research
In recent years there has been an increase in the use of biocides in
industrial, clinical and domestic
applications, this increased usage has prompted concerns that biocide
exposure may lead to biocide
resistance, which as a result of common mechanisms of resistance, will
also select for mutant bacteria
which are cross-resistant to antibiotics. There is a global reliance on
the use of antibiotics to treat bacterial
infections and the emergence of new resistant strains presents a real
global health concern.
Research conducted at the University of Birmingham by Professor Laura
Piddock (at Uob since 1987) and
Dr Mark Webber (Senior Research Fellow, at UoB since 2001)) aimed to
investigate the common
mechanistic links between resistance to the commonly used biocide,
triclosan and antibiotic resistance.
The research started in 2003, initially as part of two collaborative
projects funded by Defra (2003-2007,
OD2010: £433,925) between the University of Birmingham (Prof Laura
Piddock), Bristol University (Prof
Tom Humphrey) and the Animal Health Veterinary Laboratories Agency (Prof
Martin Woodward) and
subsequently continuing at Birmingham alone as the focus of a BBSRC David
Phillips fellowship (2007-2011,
BB/D020476/1: £451,049) and BBSRC project grant (2009-2012,
BB/G012016/1: £522,284) awarded
to Dr Mark Webber and continuing to the present.
Using Salmonella as a model food borne pathogen, the research
demonstrated that exposure to common
household biocides does select for mutant bacterial strains, which
demonstrate cross resistance to
antibiotics. Novel mechanisms of biocide resistance were identified and
the mutant strains were found not
to be severely compromised in their fitness, for example triclosan
resistant Salmonella were able to survive
in a chick colonisation model in competition with parent strains
throughout a 28 day experiment [1-4]. As a
result such mutants present a credible risk of surviving in the food chain
once selected and indeed are
indistinguishable from antibiotic resistant isolates recovered from
patients. Human infection with resistant
bacterial strains is known to be associated with higher chances of
mortality, morbidity and increased lengths
of time in hospital, with resistant Salmonella strains being associated
with a three fold higher risk of severe
illness or death than drug sensitive strains. Proteomic and transcriptomic
investigations of resistant mutants
identified novel changes to core metabolism in mutants which are relevant
to antibiotic resistance, for
example triclosan resistant mutants were found to have up-regulated a
network of proteins involved in
production of fatty acids in order to bypass the metabolic block of the
drug [5, 6]. This research has already
resulted in nine publications in internationally recognised microbiology
journals (an average impact factor of
4.93 and an average of 25 citations per publication from a total of 221 as
of March 2013).
References to the research
1. Bailey AM, Constantinidou C Ivens A, Garvey MI, Webber MA
Coldham, NG Hobman J, Wain J,
Woodward MJ, Piddock, LJV. Exposure of Escherichia
coli and Salmonella enterica serovar
Typhimurium to triclosan induces a species-specific response, including
drug detoxification. J
Antimicrob Chemother. 2009 64(5):973-985. DOI
10.1093/jac/dkp320
2. Webber MA, Randall LP, Cooles S, Woodward MJ, Piddock LJ.
Triclosan resistance in
Salmonella enterica serovar Typhimurium. J Antimicrob Chemother.
2008 62(1):83-91. DOI
10.1093/jac/dkn137
3. Randall LP, Cooles SW, Coldham NG, Penuela EG, Mott AC, Woodward MJ, Piddock
LJ, Webber
MA. Commonly used farm disinfectants can select for mutant Salmonella
enterica serovar
typhimurium with decreased susceptibility to biocides and antibiotics. J.
Antimicrob Chemother.
2007;60(6):1273-80. DOI 10.1093/jac/dkm359
4. Karatzas KA, Webber MA, Jorgensen F, Woodward MJ, Piddock
LJ, Humphrey TJ. Prolonged
treatment of Salmonella enterica serovar Typhimurium with
commercial disinfectants selects for
multiple antibiotic resistance, increased efflux and reduced invasiveness.
J Antimicrob Chemother.
2007;60(5):947-55. DOI: 10.1093/jac/dkm314
5. Webber MA, Coldham NG, Woodward MJ, Piddock LJ.
Proteomic analysis of triclosan resistance
in Salmonella enterica serovar Typhimurium. J Antimicrob
Chemother. 2008 62(1):92-7. In REF2
6. Karatzas KA, Randall LP, Webber M, Piddock LJ,
Humphrey TJ, Woodward MJ, Coldham NG.
Phenotypic and proteomic characterization of multiply antibiotic-resistant
variants of Salmonella
enterica serovar Typhimurium selected following exposure to
disinfectants. Appl Environ Microbiol.
2008;74(5):1508-16. DOI 10.1128/AEM.01931-07
Details of the impact
Antibiotic resistance is a global issue, with the number of pathogenic
bacteria being resistant to front line,
therapeutic antibiotics increasing. A recent report by the UK Chief
Medical Officer (Annual Report March
2013) detailed that that infections cost the UK economy over £30 billion
per year in economic cost and
antibiotic resistance significantly increased mortality rates (to ~30% for
infections with resistant bacteria
compared with 15% for infection with drug susceptible strains), over half
the ~5000 UK deaths from sepsis
each year caused by E. coli are a result of infection with
multiply resistant strains. The US Centres for
Disease Control and Prevention has recently estimated infections with
resistant organisms to cause over 2
million illnesses in the US per annum with over 23000 deaths resulting.
These figures demonstrate the
global nature of the problem and the impact in developed countries, the
situation is worse in the developing
world. With the increasing demand for biocide based antibacterial and
preservative products, the risk of the
emergence of new resistant strains has increased. The work described above
has had an impact on the
development of European policy and has informed the drafting of new
legislation governing the licensing
of biocidal products across the European union.
The research described above by Professor Laura Piddock and Dr Mark
Webber at the University of
Birmingham provided a scientific and mechanistic insight into how biocide
exposure can select antibiotic
resistance, proved that common mechanisms of resistance are relevant to
both biocides and antibiotics and
that mutants selected after biocide exposure are fit in animal models. The
research also identified
significant gaps in the current knowledge base regarding the mechanisms by
which bacteria respond to
biocides and commonalities with response to antibiotics, as well as a
dearth of data on biocide tolerance in
clinical and environmental isolates of pathogenic species. The impact from
these findings was the provision
of significant new information for policy makers and opinion leaders to
formulate opinions as to the safe use
of biocides and recommendations for future research priorities at a
European level (1). This report gave a
series of recommendations including instigation of research programmes to
develop surveillance
programmes to identify levels of biocide tolerance, develop standards for
testing of the propensity of
biocides to select for resistance and to monitor biocide production and
environmental accumulation levels.
The research was directly and exclusively quoted in 2010 in the EC
Scientific Committee on Consumer
Safety `Preliminary opinion on triclosan': `the identification of
mechanisms of microbial resistance including
genomic and proteomic aspects, is commendable and should be extended to
other biocides' (2).
The research has not only helped to shape EU opinion but also influenced
changes to the law governing the
use of biocides. The new `EU biocides regulation (No 528/2012)' (3) was
released in 2012 and became
legally binding across the EU from 2013. This includes requirements for
any new biocidal product to
demonstrate that it does not select resistance to itself or target
organisms before it can be registered and
used in any formulations. This legislation supersedes the previous
`Biocidal products directive'. In the UK
alone 652 biocidal products are currently licensed under the previous
directive, as detailed on the Health
and Safety Executive website of licensed biocides (4). The new regulations
influenced by this work will
apply to at least this number of products in a growing market. The
research described was highlighted in a
report published in October 2013 on antibiotic resistance in the
environment (5), which was prepared for the
Houses of Parliament by the Parliamentary Office of Science and
Technology.
All biocidal products now submitted for regulatory approval required to
be allowed to be sold in the
European Union must now have been demonstrated not to select resistance to
themselves or other
antimicrobials, this will prevent biocides being used that provide a
selective pressure that can drive
antibiotic resistance. Whilst the new legislation has only been legally
binding since September 2013 the
German federal bureau for risk management (BfR) recommended a ban on
triclosan in 2009 (6) in all non-medical
contexts, the BfR ruling relied heavily on the report mentioned
above from the EC Scientific
Committee on Consumer Safety `Preliminary opinion on triclosan' to form a
basis for its decision which in
turn used research from Birmingham to shape its conclusions. The EU in
turn imposed a similar ban across
Europe in 2010 in response to the BfR recommendation and a petition from
Ciba (the manufacturer of
triclosan) to remove triclosan from the approved list of biocidal products
(this ban was over-ruled in 2012
after appeal from users of triclosan due to procedural problems with the
original ruling, further legal
consideration is pending at the time of submission).
The work was disseminated by publication in international peer reviewed
journals, conference presentations
and informal discussion with government agencies e.g. quarterly meetings
with colleagues at DEFRA.
Sources to corroborate the impact
- SCENIHR (Scientific Committee on Emerging and Newly Identified Health
Risks), Assessment of the
Antibiotic Resistance Effects of Biocides. European Commission; 19
January 2009
http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_021.pdf
(cited on p52 and
on 86)
- SCCS (Scientific Committee on Consumer Safety), Preliminary opinion on
triclosan (antimicrobial
resistance). European Commission; 23 March, 2010
http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_013.pdf
(cited on p
50 and 2x on 55)
- Regulation (EU) No 528/2012 of the European Parliament and of the
Council of 22 May 2012
concerning the making available on the market and use of biocidal
products
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:FULL:EN:PDF
- http://webcommunities.hse.gov.uk/connect.ti/pesticides/viewdatastore?dsid=6020&adv=S
- http://www.parliament.uk/documents/POST/postpn446_Antibiotic-resistance-in-the-environmentreferences.pdf
- Bfr opinion #031/2009, 12 June 2009. Bfr supports ban on triclosan in
food contact materials.
http://www.bfr.bund.de/cm/349/bfr_supports_ban_on_triclosan_in_food_contact_materials.pdf